Antisense therapeutics: Is it as simple as complementary base recognition?

Molecular Medicine

Volumn 6, Issue 2, 2000, Pages 72-81

  Agrawal, Sudhir ^a   Kandimalla, Ekambar R ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

DRUG RESEARCH; GENE EXPRESSION; GENE TECHNOLOGY; GENE THERAPY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; REVIEW;

ANIMALS; BASE PAIRING; BASE SEQUENCE; BINDING SITES; CLINICAL TRIALS; CPG ISLANDS; DRUG DESIGN; HUMANS; IMMUNIZATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

PROKARYOTA;

EID: 0033958635     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1357-4310(99)01638-x     Document Type: Review

References (50)

1. Zamecnik, P.C. and Stephenson, M. (1978) Inhibition of Raus sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75, 280-284
2. Agrawal, S. and Zhao, Q. (1998) Antisense therapeutics. Curr. Opin. Chem. Biol. 2, 519-528
3. Agrawal, S. and Kandimalla, E.R. (1999) Medicinal chemistry of antisense oligonucleotides. In Antisense Technology in the Central Nervous System (Leslie, R. et al., eds), pp. 108-136, Oxford University Press
4. Crooke, S.T. (1998) Vitravene - another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8, vii-viii
5. Stein, C.A. (1999) Keeping the biotechnology of antisense in context. Nat. Biotechnol. 17, 209
6. McIntyre, K.W. et al. (1993) A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence specific immune stimulation. Antisense Res. Dev. 3, 309-322
7. Chen, L. et al. (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U. S. A. 95, 195-200
8. Chen, L. et al. (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5, 21-34
9. McKay, R.A. et al. (1999) Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. 274, 1715-1722
10. Kita, K. et al. (1999) Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int. J. Cancer 80, 553-558
11. Minkoff, R. et al. (1999) Antisense oligonucleotide blockade of connexin expression during embryonic bone formation: evidence of functional compensation within a multigene family. Dev. Genet. 24, 43-56
12. Kuramoto, E. et al. (1992) Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83, 1128-1131
13. Branda, R.F. et al. (1993) Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45, 2037-2043
14. Kreig, A.M. et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549
15. Zhao, Q. et al. (1996) Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51, 173-182
16. Klinman, D.M. et al. (1996) CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. U. S. A. 93, 2879-2883
17. Zhao, Q. et al. (1997) Pattern and kinetics of cytokine production following administration of phosphorothioate oligonudeotides in mice. Antisense Nucleic Acid Drug Dev. 79, 495-502
18. Krieg, A.M. (1998) Leukocyte stimulation by oligodeoxynucleotides. In Applied Antisense Oligonucleotide Technology (Stein, C.A. and Krieg, A.M., eds), pp. 431-448, Wiley-Liss, New York
19. Park, Y.G. et al. (1999) Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. Gene-specific inhibition of tumor growth. J. Biol. Chem. 274, 1573-1580
20. Sharma, N.W. et al. (1996) Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res. 16, 61-69
21. Morishita, R. et al. (1998) Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ. Res. 82, 1023-1028
22. Bock, L.C. et al. (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566
23. Rando, R.F. and Hogan, M.E. (1998) Biological activity of guanosine quartet-forming oligonucleotides. In Applied Antisense Oligonucleotide Technology (Stein, C.A. and Krieg, A.M., eds), pp. 335-352, Wiley-Liss, New York
24. Kanagaratnam, R. et al. (1998) Malaria merozoite surface protein antisense oligodeoxynucleotides lack antisense activity but function as polyanions to inhibit red cell invasion. Int. J. Biochem. Cell Biol. 30, 979-985
25. Hartmann, G. et al. (1996) Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2, 429-438
26. Patzel, V. and Sczakiel, G. (1998) Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat. Biotechnol. 16, 64-68
27. Matveeva, O. et al. (1998) Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat. Biotechnol. 16, 1374-1375
28. Tu, G-C. et al. (1998) Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J. Biol. Chem. 273, 25125-25131
29. Kandimalla, E.R. et al (1997) Single-stranded DNA and RNA targeted triplexformation: UV, CD and molecular modeling studies of foldback triplexes containing different RNA, 2′-OMe-RNAand DNA strand combinations. J. Biomol. Struct. Dyn. 14, 715-726
30. Freier, S.M. and Altmann, K.H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429-4443
31. Agrawal, S. et al. (1997) In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 7, 245-249
32. Galbraith, W.M. et al. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonudeotides in the monkey. Antisense Res. Dev. 3, 201-206
33. Shaw, D.R. et al. (1997) Effects of synthetic oligonudeotides on human complement and coagulation. Biochem. Pharmacol. 53, 1123-1132
34. Kandimalla, E.R. et al. (1998) Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Bioorg. Med. Chem. Lett. 18, 2103-2108
35. Agrawal, S. et al. (1997) Mixed-backbone oligonudeotides containing phosphorothioate and methylphosphonate linkages as second-generation antisense oligonudeotides. Nucleosides Nucleotides 16, 927-936
36. Zhang, R. et al. (1995) In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50, 545-556
37. Altmann, K-H. et al. (1996) Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 50, 168-176
38. Agrawal, S. et al. (1997) Mixed-backbone oligonudeotides as second generation antisense oligonudeotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U. S. A. 94, 2620-2625
39. Agrawal, S. et al. (1998) Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. J. Drug Targeting 5, 303-312
40. Agrawal, S. et al. (1997) Toxicological effects of an oligodeoxy-nucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 7, 575-584
41. Agrawal, S. and Zhao, Q. (1998) Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8, 135-139
42. Zhang, R. et al. (1996) Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther. 278, 971-979
43. Agrawal, S. et al. (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol 50, 571-576
44. Eckstein, F. et al. (1996) On the quality control of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 6, 149
45. Agrawal, S. et al. (1996) Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg. Med. Chem. Lett. 6, 2219-2224
46. Gao, W-Y. et al. (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol. 41, 223-229
47. Guvakova, M.A. et al. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627
48. Srinivasan, S.K. et al. (1995) Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5, 131-139
49. Wallace, T.L. et al. (1996) Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278, 1306-1312
50. Sheehan, J.P. and Lan, H-C. (1998) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92, 1617-1625